<?xml version="1.0" encoding="UTF-8"?>
<p>NDV has been applied in various clinical trials for cancer therapy. A long-term survival in phase II trials of ovarian, stomach and pancreatic cancers was observed [
 <xref rid="B171-biomedicines-08-00060" ref-type="bibr">171</xref>]. Three hundred and thirty-five individuals with colorectal cancer were immunized with NDV vectors in a phase III trial, which provided prolonged survival and improved life quality [
 <xref rid="B120-biomedicines-08-00060" ref-type="bibr">120</xref>]. However, in a randomized double-blind phase II/III trial in melanoma patients no significant differences between patients vaccinated with NDV and the placebo group were seen [
 <xref rid="B172-biomedicines-08-00060" ref-type="bibr">172</xref>]. 
</p>
